NCT00987909View on ClinicalTrials.gov

Exposure Chamber Trial With Cat Immunotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

March 31, 2010

Study Completion Date

May 31, 2010

Conditions
Cat Allergy
Interventions
BIOLOGICAL

Specific allergen immunotherapy (placebo)

Drops for sublingual administration, 0 mcg (placebo), once daily administration for 16 weeks

BIOLOGICAL

Specific allergen immunotherapy

Drops for sublingual administration, 4.5 mcg Fel d1/day, once daily administration for 16 weeks.

BIOLOGICAL

Specific allergen immunotherapy

Drops for sublingual administration, 9.0 mcg Fel d1/day, once daily administration for 16 weeks

BIOLOGICAL

Specific allergen immunotherapy

Drops for sublingual administration, 18.0 mcg Fel d1/day, once daily administration for 16 weeks

Trial Locations (1)

L4W 1N2

Cetero Research, Mississauga

Sponsors
All Listed Sponsors
collaborator

Cetero Research, San Antonio

NETWORK

lead

ALK-Abelló A/S

INDUSTRY

NCT00987909 - Exposure Chamber Trial With Cat Immunotherapy | Biotech Hunter | Biotech Hunter